Potamkin Prize for Research in Pick's, Alzheimer's, and Related Diseases

Potamkin Prize for Research in Pick's, Alzheimer's, and Related Diseases Sponsored by the AAN and the American Brain Foundation and funded through the philanthropy of the Potamkin family. This award recognizes major contributions to the understanding of the causes, prevention, treatment, and cure for Pick's, Alzheimer's, and related diseases. Presentation Recipient is expected to present a 20-minute lecture during a scientific session at the 67th AAN Annual Meeting. Recipient will receive: -- Medallion and $100,000 prize -- Complimentary registration for 67th Annual Meeting -- Recognition at 2015 Awards Luncheon at 67th Annual Meeting Eligibility Must be in any of the following biological disciplines: neurology, neuropathology, biochemistry, molecular biology, molecular genetics, chemistry, pharmacology, immunology, physiology, or cell biology Application Procedure Applicants should submit one complete set of the following materials: 1. Completed application form 2. Current curriculum vitae 3. Letter citing scientific accomplishments in detail 4. Two recommendation letters 5.Up to six selected reprints Deadline The 2015 scientific award deadline is October 23, 2014. For more information, please contact awards@aan.com.
Source: ScanGrants feed - Category: Research Authors: Source Type: funding

Related Links:

ConclusionsThis study demonstrates biomarker-based MCI prognosis and supports its role in clinical decision-making in daily practice.ResumenObjetivoEl objetivo de este estudio fue investigar el rol y pronóstico de los biomarcadores de enfermedad de Alzheimer en pacientes con diagnóstico clínico de deterioro cognitivo leve (DCL) en una clínica de memoria de Latinoamérica.MétodoOchenta y nueve pacientes con DCL, 43 con demencia tipo Alzheimer y 18 controles normales apareados por edad, sexo y escolaridad fueron estudiados con un extenso protocolo demográfico, neurológic...
Source: Neurologia - Category: Neurology Source Type: research
ConclusionsSimilar to AD, the interpretation of [18F]THK5351 uptake in PSP is likely confounded by off-target binding to MAO-B binding sites. [18F]THK5351 is not sufficient in quantifying tau aggregates in PSP using the proposed rasagiline dosing regimen.
Source: NeuroImage: Clinical - Category: Radiology Source Type: research
CONCLUSION: These findings suggested that occipitoparietal cortex, posterior cingulate cortex and precuneus, which were particularly affected by increased tau accumulation in VS-AD patients, may associate with visuospatial dysfunction of AD. PMID: 31724513 [PubMed - as supplied by publisher]
Source: Current Alzheimer Research - Category: Neurology Authors: Tags: Curr Alzheimer Res Source Type: research
Amyvid (florbetapir f18, [18F]AV ‐45, [18F]5) was the first FDA approved positron emission tomography (PET) imaging agent targeting β‐amyloid (Aβ) plaques for assisting the diagnosis of Alzheimer's disease. This work aimed to improve the [18F]AV ‐45 ([18F]5) preparation by using solid ‐phase extraction (SPE) purification. [18F]AV ‐45 ([18F]5) was synthesized by direct nucleophilic radiofluorination ofO‐tosylated precursor (1 mg) at 120 °C in anhydrous dimethyl sulfoxide (DMSO), followed by acid hydrolysis of theN‐Boc protecting group. Purification was accomplished by loading the crude reaction m...
Source: Journal of Labelled Compounds and Radiopharmaceuticals - Category: Biochemistry Authors: Tags: RESEARCH ARTICLE Source Type: research
Publication date: Available online 4 November 2019Source: NeuroImage: ClinicalAuthor(s): Iman Beheshti, Scott Nugent, Olivier Potvin, Simon DuchesneAbstractThe level of prediction error in the brain age estimation frameworks is associated with the authenticity of statistical inference on the basis of regression models. In this paper, we present an efficacious and plain bias-adjustment scheme using chronological age as a covariate through the training set for downgrading the prediction bias in a Brain-age estimation framework. We applied proposed bias-adjustment scheme coupled by a machine learning-based brain age framework...
Source: NeuroImage: Clinical - Category: Radiology Source Type: research
PET/MRI scans show middle-aged adults with high vascular risk factors have...Read more on AuntMinnie.comRelated Reading: PET, MRI show physical activity aids brain health SNMMI: Cerebrovascular risk tied to Alzheimer's disease MRI ties high blood pressure to dementia risk PET links amyloid, vascular factors to cognitive decline PET links midlife vascular risk factors to more amyloid
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Despite the importance of Aβ aggregation in Alzheimer’s disease etiology, our understanding of the sequence determinants of aggregation is sparse and largely derived from in vitro studies. For example, in vitro proline and alanine scanning mutagenesis of Aβ40 proposed core regions important for aggregation. However, we lack even this limited mutagenesis data for the more disease-relevant Aβ42. Thus, to better understand the molecular determinants of Aβ42 aggregation in a cell-based system, we combined a yeast DHFR aggregation assay with deep mutational scanning. We measured the effect of 791 of th...
Source: G3: Genes Genomes Genetics - Category: Genetics & Stem Cells Authors: Tags: Investigations Source Type: research
Publication date: Available online 1 November 2019Source: NeuroscienceAuthor(s): Hala El Khoury, John Mitrofanis, Luke A HendersonAbstractWe explore whether near infrared light can change patterns of resting (task-negative) and/or evoked (task-positive; eg finger-tapping) brain activity in normal, young human subjects using fMRI (functional magnetic resonance imaging). To this end, we used a vielight transcranial device (810nm) and compared the scans in subjects after active- and sham-light sessions. Our fMRI results showed that, while light had no effect on cerebral blood flow and global resting state brain activity (task...
Source: Neuroscience - Category: Neuroscience Source Type: research
Publication date: Available online 1 November 2019Source: NeuroImageAuthor(s): Meral A. Tubi, Franklin W. Feingold, Deydeep Kothapalli, Evan T. Hare, Kevin S. King, Paul M. Thompson, Meredith N. Braskie, Alzheimer's Disease Neuroimaging InitiativeAbstractWhite matter hyperintensities (WMH) are brain white matter lesions that are hyperintense on fluid attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI) scans. Larger WMH volumes have been associated with Alzheimer's Disease (AD) and with cognitive decline. However, the relationship between WMH volumes and cross-sectional cognitive measures has been inconsi...
Source: NeuroImage - Category: Neuroscience Source Type: research
We guide you to a country where DNA analysis dates back to at least two decades, where Game of Thrones was shot, and where more sheep live than people. To the country of Ice and Fire. In the next stop of our genomics and politics series, let’s see how Iceland, a state with a tiny and homogenous population makes use of genomic data, and how private and public clashes over its regulatory issues. To share or not to share? In the future, researchers in many countries will be able to reliably identify hundreds of people as carriers of cancer-related genes only by pressing a button. It won’t matter whether thos...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Future of Medicine Genomics Security & Privacy DNA dna testing ethics genes Genetic testing genetics technology regulations government society bioethics bioethical politics iceland decode Source Type: blogs
More News: Academies | Allergy & Immunology | Alzheimer's | Biochemistry | Biology | Brain | Chemistry | Cytology | Drugs & Pharmacology | Genetics | Molecular Biology | Neurology | Neuroscience | PET Scan | Physiology | Research